Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedSep 11, 2026
DataAggregated Company Financials
Companies1379
  • 7D-4.5%
  • 3M8.3%
  • 1Y19.7%
  • YTD7.1%

Over the last 7 days, the Healthcare industry has dropped 3.4%, driven by declines in Eli Lilly and Amgen of 3.1% and 12%, respectively. On the other hand Roivant Sciences is actually up 22%. In the past year, the industry has gained 23%. Looking forward, earnings are forecast to grow by 21% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 11 Sep 2026US$7.0tUS$3.4tUS$117.9b24.9x59.7x2.1x
Sun, 09 Aug 2026US$7.0tUS$3.4tUS$114.2b26.2x61.7x2.1x
Tue, 07 Jul 2026US$7.0tUS$3.3tUS$122.0b25.4x57.4x2.1x
Thu, 04 Jun 2026US$6.2tUS$3.3tUS$122.5b23.4x50.7x1.9x
Sat, 02 May 2026US$6.2tUS$3.3tUS$118.0b23.6x52.5x1.9x
Mon, 30 Mar 2026US$6.0tUS$3.3tUS$125.9b21.8x47.5x1.8x
Wed, 25 Feb 2026US$6.6tUS$3.3tUS$127.8b26.6x51.8x2x
Fri, 23 Jan 2026US$6.7tUS$3.2tUS$130.5b27.9x51x2.1x
Sun, 21 Dec 2025US$6.5tUS$3.2tUS$135.2b26.2x48x2x
Tue, 18 Nov 2025US$6.2tUS$3.2tUS$133.4b25.6x46.8x2x
Thu, 16 Oct 2025US$5.9tUS$3.1tUS$140.4b24.5x42.3x1.9x
Sat, 13 Sep 2025US$5.8tUS$3.1tUS$137.6b22.7x42.1x1.9x
Mon, 11 Aug 2025US$5.4tUS$3.1tUS$139.7b23.3x38.5x1.7x
Wed, 09 Jul 2025US$5.5tUS$3.0tUS$127.9b24.2x42.9x1.8x
Fri, 06 Jun 2025US$5.4tUS$3.0tUS$127.2b23.4x42.8x1.8x
Sun, 04 May 2025US$5.6tUS$2.7tUS$126.2b24.8x44.1x2x
Tue, 01 Apr 2025US$5.6tUS$2.6tUS$81.9b26.3x69x2.1x
Thu, 27 Feb 2025US$5.9tUS$2.6tUS$79.6b25.5x73.7x2.2x
Sat, 25 Jan 2025US$6.0tUS$2.9tUS$85.5b27.9x70.7x2.1x
Mon, 23 Dec 2024US$5.8tUS$2.9tUS$78.2b27.7x73.5x2x
Wed, 20 Nov 2024US$5.9tUS$2.9tUS$76.7b27.1x77.3x2x
Fri, 18 Oct 2024US$6.2tUS$2.8tUS$58.6b31.2x106.6x2.2x
Sun, 15 Sep 2024US$6.3tUS$2.8tUS$60.0b30.6x105.4x2.2x
Tue, 13 Aug 2024US$6.0tUS$2.8tUS$55.3b30.1x108.9x2.1x
Thu, 11 Jul 2024US$6.2tUS$2.8tUS$62.2b30x99x2.2x
Sat, 08 Jun 2024US$6.2tUS$2.8tUS$63.7b30x97.5x2.2x
Mon, 06 May 2024US$6.0tUS$2.8tUS$65.2b31.1x92.6x2.1x
Wed, 03 Apr 2024US$6.3tUS$2.8tUS$84.0b32.5x74.9x2.3x
Fri, 01 Mar 2024US$6.3tUS$2.8tUS$84.2b30.9x74.6x2.3x
Sun, 28 Jan 2024US$6.3tUS$2.8tUS$90.7b32x69.7x2.2x
Tue, 26 Dec 2023US$6.2tUS$2.8tUS$91.5b33.1x67.4x2.2x
Thu, 23 Nov 2023US$5.8tUS$2.8tUS$91.2b28x63.5x2.1x
Sat, 21 Oct 2023US$5.7tUS$2.8tUS$99.6b25.6x57.7x2.1x
Mon, 18 Sep 2023US$6.0tUS$2.8tUS$98.6b29.3x61x2.2x
Price to Earnings Ratio

61x


Total Market Cap: US$6.0tTotal Earnings: US$98.6bTotal Revenue: US$2.8tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 65.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 60.2x which is lower than its 3-year average PE of 65.5x.
  • The industry is trading close to its 3-year average PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 6.0% per year over the last three years.
  • Revenues for these companies have grown 6.7% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market-2.20%
Healthcare-4.47%
Healthcare Services-2.35%
Life Sciences-3.83%
Pharma-3.98%
Medical Equipment-5.83%
Biotech-5.86%
Healthtech-8.25%
Industry PE
  • Investors are most optimistic about the Life Sciences industry, which is trading close to its 3-year average PE ratio of 55.3x.
    • Analysts are expecting annual earnings growth of 18.8%, which is higher than its past year's earnings growth of 9.6% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 29% over the next 5 years.
  • However this is lower than its past earnings growth rate of 65% per year.
  • In contrast, the Healthcare Services industry is expected to see its earnings grow by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ROIV Roivant SciencesUS$40.9419.0%
+US$4.7b		184.1%PS3926.2x
HCA HCA HealthcareUS$421.212.9%
+US$2.6b		4.6%PE13.3x
UTHR United TherapeuticsUS$503.862.8%
+US$584.2m		24.5%PE16.5x
TXG 10x GenomicsUS$66.385.0%
+US$411.7m		408.3%PS14x
ELV Elevance HealthUS$416.540.4%
+US$381.7m		32.3%PE18.2x

Latest News

PACS
US$44.85
PACS Group
7D
4.1%
1Y
367.2%
MRK
US$144.71
Merck
7D
-5.0%
1Y
69.9%
JNJ
US$266.35
Johnson & Johnson
7D
-4.3%
1Y
49.2%
SYK
US$270.01
Stryker
7D
-12.3%
1Y
-30.6%
Narrative Update • Sep 09

SYK: Hospital Digitization And Cyber Resilience Will Underpin Post Cyberattack Recovery

Stryker's updated analyst price target has edged lower in line with a reduced fair value estimate of about $376, as analysts weigh slightly softer revenue growth and profit margin assumptions, along with a more conservative future P/E outlook following recent revisions across the MedTech coverage group. Analyst Commentary Recent Street research on Stryker shows a mix of confidence in the company’s long term growth drivers and concern about near term execution risks, especially around 2026 guidance and the impact of operational disruptions.
TXG
US$66.38
10x Genomics
7D
5.0%
1Y
408.3%
UTHR
US$503.86
United Therapeutics
7D
2.8%
1Y
24.5%
UNH
US$388.28
UnitedHealth Group
7D
-3.2%
1Y
9.8%
VRTX
US$514.56
Vertex Pharmaceuticals
7D
-7.8%
1Y
29.5%
Seeking Alpha • Sep 09

Vertex Pharmaceuticals: Solid Growth But Valuation Still Requires Flawless Execution

Summary Vertex Pharmaceuticals Incorporated (VRTX) remains a 'Hold' as upside is constrained by valuation and execution risks outside cystic fibrosis. Vertex’s cystic fibrosis franchise continues robust 11% Y/Y growth, but dependency remains high at 96% of product revenues. New launches — JOURNAVX, CASGEVY, and the Crinetics acquisition — show promise but face commercialization and margin headwinds. Elevated SG&A growth and product mix shifts are pressuring margins; further upside depends on successful execution of new assets. Read the full article on Seeking Alpha
HCA
US$421.21
HCA Healthcare
7D
2.9%
1Y
4.6%
AMGN
US$382.47
Amgen
7D
-13.9%
1Y
35.3%
ROIV
US$40.94
Roivant Sciences
7D
19.0%
1Y
184.1%
ABT
US$103.36
Abbott Laboratories
7D
-5.0%
1Y
-22.1%
CLOV
US$4.71
Clover Health Investments
7D
10.7%
1Y
50.0%
LLY
US$1,123.00
Eli Lilly
7D
-3.2%
1Y
48.5%
Narrative Update • Sep 05

LLY: Incretin Obesity Franchise And Pipeline Will Support Premium Positioning Beyond 2030

The analyst fair value estimate for Eli Lilly has been raised from $1,500 to $1,600 as analysts point to strong Q2 incretin volume, obesity drug demand, and upgraded multi-year guidance as key supports for higher long-term assumptions. Analyst Commentary Recent Street research on Eli Lilly points to a broadly constructive tone, with many bullish analysts lifting price targets after Q2 results and updated guidance.
ELV
US$416.54
Elevance Health
7D
0.4%
1Y
32.3%
GRDN
US$43.83
Guardian Pharmacy Services
7D
9.2%
1Y
44.7%